AVIGA3 (Cohort 2.0)
ConditionMaculopathy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-99
SponsorTan Tock Seng Hospital
About this trial
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
Eligibility criteria
Qualifiers
Subjects in the age group ≥ 50 to 99 years old.
Both genders
Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.
Able to turn on and connect the web-camera to a computer independently or with the help of family.
Disqualifiers
Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.
Unable to turn on and connect the web-camera to a computer independently.
Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months
Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
Trial design
Treatments tested in this trial
- Amsler Grid
- AVIGA
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov